Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab Drug-Drug Interaction Study in Rheumatoid Arthritis
NCT04246762Phase 1Completed
- Sponsor
- R-Pharm
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of olokizumab in rheumatoid arthritis (RA), sponsored by R-Pharm. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity at Day 22, Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration at Day 22 and 1 more. Started Nov 2021; status: completed.
02
Drugs
olokizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04246762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246762.